Pfizer's Outlook Improves

Pfizer’s Outlook Improves
Having spent $5 billion on research and development in 2002, Pfizer (NYSE: PFE) is king of the drug world. And with its $60 billion Pharmacia merger completed in April, the king just got fatter

0 Comments/

0 Likes

/0 Tweets/in General Biotechnology

June 19, 2003

19 Jun 2003

Schering's Dr. Feelbetter?

Schering’s Dr. Feelbetter?
Fred Hassan is out to revive the drugmaker. It’s a big job

0 Comments/

0 Likes

/0 Tweets/in General Biotechnology

June 19, 2003

19 Jun 2003

FDA approves first nasal mist flu vaccine

FDA approves first nasal mist flu vaccine
Most people who avoid flu shots because they fear needles will not have that excuse this season. The Food and Drug administration has approved a flu vaccine that is delivered by a squirt up the nose instead of a shot in the arm.

0 Comments/

0 Likes

/0 Tweets/in General Biotechnology

June 19, 2003

19 Jun 2003

Microsoft loses No. 2 ranking in market value to drug maker

Microsoft loses No. 2 ranking in market value to drug maker
Microsoft has lost its status as the world’s second-largest corporation to drug maker Pfizer due to slowing sales growth that caused it to miss out on this year’s stock-market rally.

0 Comments/

0 Likes

/0 Tweets/in General Biotechnology

June 19, 2003

19 Jun 2003

Report Says More Farmers Don't Follow Biotech Rules

Report Says More Farmers Don’t Follow Biotech Rules
A new study, drawn from government data, shows that more farmers are failing to comply with standards governing the planting of genetically modified corn than the industry has claimed.

Nearly one-fifth of farms growing the main type of genetically engineered corn, BT corn, are violating government rules aimed at preserving the usefulness of the corn, a consumer group said yesterday.